The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2026 | Insights into fragmentomic and genomic profiling of cfDNA to track tumor burden in multiple myeloma
Dory Abelman, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses his presentation on fragmentomic and genomic profiling of cell-free DNA (cfDNA) to track tumor burden in multiple myeloma. Dr Abelman notes that his team’s study found that peripheral blood cfDNA can recover a significant proportion of bone marrow-derived lesions, and that certain features of cfDNA may inform risk of early progression. This discussion took place at the 3rd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2026), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
